Kwon V. Lutheran General Hospital, Inc
Author | : |
Publisher | : |
Total Pages | : 16 |
Release | : 1999 |
Genre | : |
ISBN | : |
Download Kwon V. Lutheran General Hospital, Inc Book in PDF, ePub and Kindle
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Kwon V Lutheran General Hospital Inc PDF full book. Access full book title Kwon V Lutheran General Hospital Inc.
Author | : |
Publisher | : |
Total Pages | : 16 |
Release | : 1999 |
Genre | : |
ISBN | : |
Author | : |
Publisher | : |
Total Pages | : 60 |
Release | : 1992 |
Genre | : Legal briefs |
ISBN | : |
Author | : |
Publisher | : |
Total Pages | : 40 |
Release | : 1987 |
Genre | : Legal briefs |
ISBN | : |
Author | : |
Publisher | : |
Total Pages | : 18 |
Release | : 1977 |
Genre | : |
ISBN | : |
Author | : |
Publisher | : |
Total Pages | : 0 |
Release | : 1987 |
Genre | : Legal briefs |
ISBN | : |
Author | : |
Publisher | : |
Total Pages | : 0 |
Release | : 1986 |
Genre | : Legal briefs |
ISBN | : |
Author | : Aspen Health Law Center |
Publisher | : Jones & Bartlett Learning |
Total Pages | : 158 |
Release | : 1998 |
Genre | : Antitrust law |
ISBN | : 9780834212275 |
Antitrust laws touch upon a wide range of conduct and business relationships in the delivery of health care services, and the issues that should be of concern to health care organizations are described. Health Care Antitrust provides practical overviews of the principal legal issues relating to health care antitrust, as well as a general understanding of antitrust analysis as applied to contractual relationships and business strategies that present antitrust risks in a managed care environment.
Author | : Anonymous |
Publisher | : Legare Street Press |
Total Pages | : 0 |
Release | : 2022-10-27 |
Genre | : |
ISBN | : 9781018977065 |
This work has been selected by scholars as being culturally important, and is part of the knowledge base of civilization as we know it. This work is in the "public domain in the United States of America, and possibly other nations. Within the United States, you may freely copy and distribute this work, as no entity (individual or corporate) has a copyright on the body of the work. Scholars believe, and we concur, that this work is important enough to be preserved, reproduced, and made generally available to the public. We appreciate your support of the preservation process, and thank you for being an important part of keeping this knowledge alive and relevant.
Author | : Carrie P. Hunter |
Publisher | : CRC Press |
Total Pages | : 591 |
Release | : 2000-03-01 |
Genre | : Medical |
ISBN | : 0824746457 |
This book presents comprehensive assessment and up-to-date discussion of the epidemiology, prevention, and treatment of cancer in the elderly, highlighting the growing demands of the disease, its biology, individual susceptibility, the impact of state-of-the-art and emerging therapies on reducing morbidity, and decision making processes. Describ
Author | : Michael J. Klepper |
Publisher | : Jones & Bartlett Learning |
Total Pages | : 332 |
Release | : 2011 |
Genre | : Medical |
ISBN | : 0763769126 |
Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk provides pharmaceutical scientists, researchers and technicians with an accessible, practical framework for the analysis, summary and interpretation of drug safety data. The only guide of its kind, Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk is an invaluable reference for premarketing risk assessment. This unique resource enhances the ability of pharmaceutical professionalsùthose with and without clinical trainingùto determine the risk of a drug or biologic ahead of its release, thereby reducing unnecessary jeopardy to the patient. Authors Dr. Michael Klepper and Dr. Barton Cobert, who together bring decades of pharmaceutical research and drug safety expertise, discuss how quality planning, safety training and data standardization result in significant cost, time and resource savings. Through illustrative, step-by-step instruction, Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk provides the definitive guide to drug safety data analysis and reporting. Key features include: Step-by-step instruction on how to analyze, summarize and interpret safety data for mandatory governmental safety reports Pragmatic tipsàand mistakes to avoid Simple explanations of what safety data are collected, and what the data mean Practical approaches to determining a drug effect and understanding its clinical significance Guidance for determining risk throughout the lifecycle of a drug, biologic or nutraceutical Examples of user-friendly data displays that enhance safety signal identification Ways to improve data quality and reduce the time, resources and costs involved in mandatory safety reporting Relevant material for the required training of drug safety/pharmacovigilance professionals SPECIAL FEATURE: Actual examples of an Integrated Analysis of Safety (IAS) -used in the preparation of the Integrated Summary of Safety (ISS) and the Summary of Clinical Safety (SCS) reports -, and the Periodic Safety Update Report (PSUR)